Research programme: heat shock protein 90 inhibitors - Locus
Alternative Names: Heat shock protein 90 inhibitors research programme - Locus; HSP90 inhibitors - LocusLatest Information Update: 04 Nov 2017
At a glance
- Originator Locus Pharmaceuticals
- Developer Locus Pharmaceuticals; National Cancer Institute (USA)
- Class
- Mechanism of Action Heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 21 Jan 2010 This research programme is still in active development
- 13 Jan 2005 Preclinical trials in Cancer in USA (unspecified route)